Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ciclosporin A ophthalmic - Laboratorios Sophia/Alcon

Next Previous
Drug Profile

Ciclosporin A ophthalmic - Laboratorios Sophia/Alcon

Alternative Names: Alcon; Cyclosporine opthalmic solution; ST-603; Zyclorin

Latest Information Update: 05 Aug 2013

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Laboratorios Sophia
  • Developer Alcon
  • Class Anti-inflammatories; Antineoplastics; Antipsoriatics; Antirheumatics; Ciclosporins; Eye disorder therapies; Heart failure therapies; Neuroprotectants
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Dry eyes

Most Recent Events

  • 30 Mar 2013 Discontinued - Phase-III for Dry eyes in USA (Topical)
  • 30 Mar 2012 No development reported - Phase-III for Dry eyes in USA (Topical)
  • 26 Aug 2010 Alcon has been acquired by Novartis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top